You needed to pick up an unfamiliar analytical framework in less than a week for a high-stakes review. Choose a real case. Lay out your day-by-day learning plan, the minimum viable artifacts you created, how you checked correctness while time-constrained, and the trade-offs you accepted. Give objective indicators that your ramp-up succeeded or fell short, and explain how you would adjust the plan if the deadline were pulled in by 48 hours.

Overview: This question tests how quickly a candidate can learn and use a new analytical framework, assessing fast onboarding, prioritization, creation of minimum viable artifacts, validation under deadline pressure, and trade-off choices.

Solution

Example Context

Scope: A high-stakes product review required a causal estimate of a policy change’s effect on DAU and 7-day retention. A randomized experiment had been stopped because of an infrastructure problem, so I had to find a credible observational approach within one week. New framework: Bayesian Structural Time Series (BSTS) using the CausalImpact method to build a counterfactual from control series and estimate the treatment effect with uncertainty. Stakeholders: Product, Engineering, Data Science, and an executive sponsor who wanted a go/no-go decision on full rollout. Assumptions (stated up front):

• The pre-period is long enough to capture seasonality and trends ($\ge 90$ days).
• Covariates are predictive and not influenced by the treatment (no leakage).
• The post-period is short ($\approx 2$ weeks), so uncertainty will be substantial.

Plan by Day (5 working days)

Day 1 — Problem framing and feasibility

• Clarify the decision question, KPIs, and acceptable uncertainty (for example, “OK if 95% interval width $\le 2$ pp”).
• Inventory the data: outcome series, candidate control series (peer geographies, older cohorts), and known events (holidays, outages).
• Skim core materials: CausalImpact vignettes, BSTS model structure (local level/trend, seasonality, spike-and-slab regression), and leakage pitfalls.
• Define the MVE (minimum viable estimate): one primary KPI (DAU), one secondary (7-day retention), a single model variant, and at least two high-ROI validation checks.

Day 2 — First working prototype

• Build a reproducible notebook with a well-tested library (R CausalImpact or the Python causal_impact equivalent).
• Preprocess: align calendars, drop outlier days, z-score covariates, and hold out a validation window.
• Fit a baseline model with a 120-day pre-period and 14-day post-period; include weekday seasonality and 5–10 control series.
• Produce a first cut: point estimate, 95% posterior intervals, and time-series plots.

Day 3 — Validation and leakage control

• Placebo tests: rotate the “treated” label across comparable geographies or time windows; confirm the observed effect sits in the extreme tail of the placebo distribution.
• Backtesting: rolling-origin forecasts entirely inside the pre-period; compute RMSPE and the calibration of posterior intervals.
• Sensitivity: remove the top predictors; vary the pre-period length; check prior sensitivity for state components.
• Quick triangulation with a simpler method (two-way fixed-effects DiD with geography and calendar fixed effects) to see whether effect direction and magnitude roughly agree.

Day 4 — Harden and communicate

• Lock the covariate set after leakage checks (exclude any series that moved after treatment).
• Document assumptions, diagnostics (RMSPE, coverage), and sensitivity grids.
• Create decision-ready artifacts: a 1-page executive summary, appendix slides with diagnostics, and a reproducible notebook.
• Peer review: a 30-minute data science peer pass for sanity and failure-mode audit.

Day 5 — Final review and contingency

• Run through with PM/Eng to align on interpretation and caveats.
• Precompute alternative slices (by platform or region) only if they meet minimum sample thresholds.
• Prepare a contingency slide with trade-offs in case you are asked to expand or contract scope.

Minimum Viable Artifacts (produced)

• A one-page decision memo covering the question, method, headline effect, uncertainty, assumptions, and recommended decision.
• A reproducible notebook with data prep, model fit, diagnostics, and plots (seeded for determinism).
• A data dictionary listing sources, transformations, and filters.
• A validation checklist with placebo/backtest results, a sensitivity table, and leakage checks.
• A 5–7 slide deck for executives, plus an appendix with methodology.

Validation Under Time Pressure

• Pre-period fit quality: RMSPE and posterior predictive checks. Target RMSPE $<3\%$ for DAU; $<5\%$ for retention.
• Placebo tests: effect percentile versus 50+ placebo geographies/windows; empirical p-value.
• Backtests: rolling-origin 7-day forecasts; coverage of 95% intervals $>90\%$.
• Triangulation: compare with DiD (two-way fixed effects). Directional agreement and overlapping intervals are a positive signal.
• Leakage checks: remove any covariate with a significant post-period shift correlated with treatment. Illustrative results (numbers from the actual run):
• Pre-period RMSPE (DAU): 2.1%; backtest coverage: 92%.
• Estimated DAU lift: +1.8% [0.5%, 3.0%] over 14 days; retention: +0.4 pp [0.1 pp, 0.7 pp].
• Placebo distribution: observed effect at the 97th percentile (empirical $p \approx 0.03$).
• DiD estimate: +1.6% [0.2%, 3.1%] — intervals overlap and direction matches.

Trade-offs Made

• Picked a well-documented off-the-shelf BSTS instead of a custom model to save time; accepted limited hyperparameter exploration.
• Limited the analysis to one primary KPI and one secondary to keep validation focused.
• Curated eight high-signal control series to cut computation and overfitting risk; did not pursue automated feature search beyond spike-and-slab.
• The short post-period (14 days) increased uncertainty; accepted wider intervals with stronger placebo evidence.

Objective Signals of Success/Failure

Success signals observed:

• Quantitative: low RMSPE, good coverage, strong placebo separation, and agreement with triangulation.
• Process: peer review passed with only minor comments; reproducibility was confirmed by reruns (same seed → same summary stats).
• Outcome: the executive accepted the recommendation; a later staged geo A/B two weeks later yielded +1.5% [0.4%, 2.6%], within our credible interval. Potential failure signals to watch:
• High pre-period error or poor coverage; an effect not distinguishable from the placebo distribution; large swings under small modeling changes; covariate leakage detected.

How I’d Update If Deadline Moved Up by 48 Hours

Time compression strategy (focus on decision usefulness, not exhaustiveness):

• Scope cut: only DAU, one geo-grouping, and one model variant.
• Method simplification: begin with two-way fixed-effects DiD (geo and calendar fixed effects, robust standard errors). Use BSTS only if DiD diagnostics pass quickly and time allows.
• Validation triage: keep the two highest-ROI checks — placebo over time windows and pre-period backtest; drop the extended sensitivity grid.
• Covariate discipline: use a pre-vetted set of controls (historically predictive, known non-reactive) to avoid leakage work.
• Communication: deliver a one-page decision with clear caveats and a risk register; propose a follow-up validation plan after the decision. Compressed 3-day plan:
• Day 1: frame the question, assemble data, run a DiD baseline with diagnostics; produce an early read.
• Day 2: run a minimal BSTS with vetted controls; quick placebo and backtest; reconcile with DiD.
• Day 3: finalize the memo and slides; peer spot-check; deliver. Guardrails in the compressed plan:
• Precommit to thresholds (e.g., require placebo $p<0.1$ and backtest coverage $>85\%$); if not met, escalate uncertainty and recommend a staged rollout rather than full launch.

Pitfalls and How I Avoided Them

• Covariate leakage: excluded any series showing contemporaneous jumps after the policy; preferred upstream, non-treated signals.
• Seasonality and holidays: included weekday factors and explicit holiday dummies.
• Data quality: monitored missingness and outliers; winsorized extreme days with documented rationale.
• Over-interpretation: reported point estimates with credible intervals and emphasized decision thresholds, not single-number precision.